S-ClassAbout S-Class
M
MRKAI Stock Diagnostic Report
Wolfe Research raises Merck stock price target on cancer drug data
Wolfe Research has raised its price target for Merck based on oncology data.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$150.66000366210938Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support126.22
Near-Term Resistance154.49
02
FUNDAMENTALS
Financial & Fundamental Analysis
Wolfe Research's upward adjustment of the target price reaffirms the value of the company's core portfolio of oncology data, positively impacting the reassessment of the company's value.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $150.66 is close to the 20-day resistance level of $154.49, and since it is in the overbought range, risk management based on the 20-day support level of $126.22 is necessary.
Support126.22
Resistance154.49
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The upward revision of target prices by securities firms, based on positive clinical and research data related to anticancer drugs, serves as a strong momentum that stimulates short-term buying interest.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-25)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.